司美格鲁肽对肥胖青少年胰岛素敏感性和心血管代谢危险因素的影响:STEP TEENS研究
STEP TEENS 3a期随机研究的二次分析,纳入193例12至<18岁无2型糖尿病的肥胖青少年,比较每周皮下注射司美格鲁肽2.4 mg与安慰剂至第68周的变化。司美格鲁肽组空腹胰岛素、HOMA-IR、ALT、腰高比、甘油三酯、LDL-C和总胆固醇降幅均大于安慰剂组,BMI降幅≥20%者的改善更明显。
要点
- 司美格鲁肽2.4 mg可改善肥胖青少年的胰岛素敏感性和血糖指标。
- 该治疗同时降低ALT、甘油三酯、LDL-C和总胆固醇等心血管代谢危险因素。
- BMI降幅≥20%者的胰岛素敏感性和心血管代谢指标改善更明显。
核心结论
- 司美格鲁肽2.4 mg是肥胖青少年的有效减重治疗,并伴随胰岛素敏感性、血糖指标、ALT及其他心血管代谢危险因素的改善。
研究设计与样本
- STEP TEENS(NCT04102189)3a期随机研究的二次分析,纳入12至<18岁肥胖青少年,193例无2型糖尿病者纳入分析,司美格鲁肽2.4 mg组129例、安慰剂组64例,比较基线至第68周的变化。
主要发现
- 空腹血清胰岛素降幅-33.6% vs -10.1%(P=0.0012),HOMA-IR降幅-35.0% vs -5.3%(P=0.0002)。
- 糖化血红蛋白P<0.0001、空腹血糖P=0.0181,ALT降幅-17.9% vs -3.3%(P=0.0232)。
- 腰高比P<0.0001、甘油三酯P<0.0001、LDL胆固醇P=0.0105、总胆固醇P<0.0001。
- 第68周BMI相对安慰剂估计差异为-16.7个百分点(P=0.0001)。
- BMI降幅≥20%者较<20%者在胰岛素敏感性、血糖指标和心血管代谢危险因素方面改善更明显。
临床怎么用
- 对无2型糖尿病的肥胖青少年,司美格鲁肽2.4 mg每周皮下注射可作为减重治疗选择,并应关注胰岛素敏感性、血糖、ALT和血脂的同步改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This secondary analysis of the Semaglutide Treatment Effect in People with obesity (STEP) TEENS (NCT04102189) study investigated the effect of semaglutide 2.4 mg versus placebo on insulin sensitivity and cardiometabolic risk factors. RESEARCH DESIGN AND METHODS: The STEP TEENS phase 3a randomized study in adolescents (aged 12 to <18 years) with obesity demonstrated that once-weekly subcutaneous semaglutide 2.4 mg provided a significantly greater percentage reduction in BMI than placebo at week 68 (estimated difference -16.7 percentage points; P = 0.0001). This analysis investigated changes in insulin sensitivity and cardiometabolic risk factors from baseline to week 68. RESULTS: Overall, 193 participants without type 2 diabetes were included in the analysis. Participants receiving semaglutide 2.4 mg (n = 129) compared with those receiving placebo (n = 64) had greater reductions from baseline in fasting serum insulin (-33.6% vs. -10.1%; P = 0.0012), homeostatic model assessment for insulin resistance (HOMA-IR) score (-35.0% vs. -5.3%; P = 0.0002), glycemic measures (glycated hemoglobin: P < 0.0001; fasting plasma glucose: P = 0.0181), alanine aminotransferase (ALT; -17.9% vs. -3.3%; P = 0.0232), waist-to-height ratio (P < 0.0001), triglycerides (P < 0.0001), LDL cholesterol (P = 0.0105), and total cholesterol (P < 0.0001). Moreover, greater improvements in insulin sensitivity, glycemic measures, and cardiometabolic risk factors were seen in semaglutide 2.4 mg recipients with BMI reductions of ≥20% versus <20%. CONCLUSIONS: These novel data support semaglutide 2.4 mg as an efficacious obesity treatment in adolescents with obesity and advance its application by showing associated improvements in insulin sensitivity, glycemic measures, ALT, and other cardiometabolic risk factors.
引用
- Arslanian S, Gies I, Goldman B, et al. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care. 2026. PMID: 41296499. doi:10.2337/dc25-0824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。